Scholars Central

Conference abstractPublished 14 May 2012

Engineering multifunctional nanoparticles to selectively target multiple myeloma cells and overcome cell adhesion mediated drug resistance.

Authors: Basar Bilgicer, Tanyel Kiziltepe, Jonathan D. Ashley, Jared F. Stefanick

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In the continuing search for effective treatments for cancer, here we report the rational engineering of a novel multifunctional nanoparticle that combines traditional chemotherapy with cell targeting and anticellular-adhesion functionalities to selectively target multiple myeloma (MM) cells and overcome cell adhesion-mediated drug resistance (CAM-DR). Anti-cellular-adhesion evolves as a promising target in oncology. VLA-4-mediated adhesion to the bone marrow extracellular matrix and stromal cells confers MM cells with CAM-DR. In our design, we used micellar nanoparticles as dynamic self-assembling scaffolds to present VLA-4-antagonist peptides and doxorubicin conjugates simultaneously to selectively target MM cells and to overcome CAM-DR. Doxorubicin was conjugated to the nanoparticles through an pH-sensitive hydrazone bond to prevent premature release and thus non-specific toxicity. Peptides were conjugated via a multifaceted synthetic procedure for generating precisely controlled number of targeting functionalities per nanoparticle. The nanoparticles, which exhibited a size of ~20nm, were efficiently internalized by MM cells with an optimal peptide valency of 20 per micelle, and induced cytotoxicity to MM cells. Mechanistic studies revealed that nanoparticles induced DNA double strand breaks as evidenced by H2AX phosphorylation, and triggered apoptosis, which was associated with PARP and caspase-8 cleavage. Importantly, multifunctional nanoparticles were more efficacious than doxorubicin in the presence of fibronectin (IC50=0.15�0.04 M and 0.42�0.09 M, respectively), and overcame CAM-DR induced by adherence of MM cells to fibronectin. Finally, in a MM xenograft model, nanoparticles preferentially homed to MM tumors, with a ~10 fold more drug accumulation when compared to doxorubicin, and demonstrated dramatic tumor growth inhibition with much reduced overall systemic toxicity. Taken together, we demonstrate the disease-driven engineering of a nanoparticlebased drug delivery system, enabling the model of an integrative approach in the treatment of MM.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiosensors & Bioelectronics
  • SubjectNanotechnology
  • SubjectEngineering
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Basar Bilgicer”
  • BylineArticles whose byline prints “Tanyel Kiziltepe”
  • BylineArticles whose byline prints “Jonathan D. Ashley”
  • BylineArticles whose byline prints “Jared F. Stefanick”